Adrian Tomasz Nowak

Mr. Adrian Tomasz Nowak

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Archives of Virology
Verified
Journal Article
Open access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
KNKlaudia Nowak
Klaudia Nowak
DLDominika Lorek
Dominika Lorek
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
ARAnna Romac
Anna Romac
JJJakub Janczura
Jakub Janczura
Human immunodeficiency virus (HIV) remains a global public health challenge, affecting millions worldwide despite significant advancements in antiretroviral therapy (ART). While ART has transformed HIV into a manageable chronic condition, long-term adherence, drug resistance, and access disparities continue to hinder treatment success. Recent research has focused on developing alternative therapeutic strategies, particularly long-acting injectable (LAI) therapies and immunotherapeutic approaches to improve adherence and potentially achieve viral remission. This review explores the evolution of pharmacological advancements in HIV treatment, highlighting the transition from daily oral ART to long-acting formulations such as cabotegravir, rilpivirine, and lenacapavir. LAI therapies reduce the burden of daily adherence, enhance treatment efficacy, and decrease stigma, particularly in vulnerable populations. Additionally, novel immunotherapeutic strategies such as broadly neutralizing antibodies, immune checkpoint inhibitors, and chimeric antigen receptor T cell therapy are being investigated for their potential to induce long-term viral suppression or cure. Despite these promising developments, several challenges remain, including resistance-associated mutations, accessibility issues, and long-term safety concerns. This review summarizes recent clinical trials, discusses the benefits and limitations of emerging HIV therapies, and outlines future research directions. The continued advancement of LAI therapies and immunotherapeutics holds great potential to improve treatment outcomes, expand global access to care, and move closer to a functional cure for HIV.

20 November 2025 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
KNKlaudia Nowak
Klaudia Nowak
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
AJAleksandra Jabłońska
Aleksandra Jabłońska
APAnna Potaczek
Anna Potaczek
JSJulia Salacha
Julia Salacha
JJJakub Janczura
Jakub Janczura
The global increase in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects more than one-third of the general population and up to 70% of individuals with type 2 diabetes or obesity, is a critical public health challenge. Given that liver steatosis is often asymptomatic until the advanced stages of disease, early detection is essential to prevent its progression to fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma. However, liver biopsy, the gold-standard diagnostic method, is invasive, costly, and unsuitable for large-scale screening. As a result, noninvasive tests have emerged as practical alternatives, particularly in primary care settings, where early identification is most feasible. The present study explored current perspectives of noninvasive liver disease screening tools and their implementation in primary care. Serum-based indices, along with imaging techniques, have demonstrated promise in identifying patients with advanced fibrosis. Novel biomarkers, including the enhanced liver fibrosis test and Pro-C3, as well as emerging artificial intelligence-assisted diagnostic platforms, yield improved accuracy and risk stratification potential. Despite accumulating evidence supporting the clinical utility and cost-effectiveness of noninvasive tests, several barriers hinder their routine use in primary care settings, which include limited funding, lack of standardized guidelines, insufficient clinician training, and disparities in access to diagnostic tools. The implementation of structured stepwise screening models has demonstrated improved diagnostic efficiency and reduced unnecessary referrals. Future research should emphasize the integration of artificial intelligence, portable diagnostic devices, and personalized risk models to enhance early detection. Ensuring widespread adoption requires coordinated efforts in policy development, provider education, and health-system investment. Noninvasive screening tools offer a feasible and cost-effective pathway for the early detection of MASLD in primary care; however, their successful implementation depends on addressing logistical, educational, and systemic barriers.

5 November 2025 in Livers
Verified
Journal Article
Open access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
AJAleksandra Jabłońska
Aleksandra Jabłońska
APAnna Potaczek
Anna Potaczek
JSJulia Salacha
Julia Salacha
JJJakub Janczura
Jakub Janczura
Herb-induced liver injury (HILI) is an increasingly recognized cause of liver damage, associated with the widespread global use of herbal products. Despite its rising incidence, HILI remains underrecognized and underreported due to the absence of specific biomarkers, limited regulatory oversight, and the complexity of multi-ingredient formulations. Diagnostic efforts rely heavily on the Roussel Uclaf Causality Assessment Method (RUCAM), with clinical presentations often nonspecific and dominated by hepatocellular patterns of injury. Epidemiological data demonstrate regional variation, with notably higher case numbers in Asia and the Americas. Mechanistically, HILI may result from either intrinsic (predictable, dose-dependent) or idiosyncratic (unpredictable, immune-mediated) reactions. Genetic predispositions, including certain HLA alleles, have been identified as risk factors. Hepatotoxicity is often linked to specific phytochemicals such as pyrrolizidine alkaloids, catechins, anthraquinones, and diterpenoids, which may contribute to oxidative stress, mitochondrial damage, or immune activation. Additionally, product inconsistencies and contamination complicate risk assessment and safety evaluation. Current management focuses on immediate discontinuation of the suspected product and supportive care, though severe cases may require liver transplantation. Future directions include the development of specific diagnostic tools, implementation of globally harmonized regulatory standards, improved pharmacovigilance systems, and enhanced public and professional education. Addressing these priorities is crucial for reducing HILI-related morbidity while supporting the safe use of herbal therapies.

16 September 2026 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
ARAnna Romac
Anna Romac
PJPaulina Jaskulska
Paulina Jaskulska
WSWeronika StęPień
Weronika StęPień
JJJakub Janczura
Jakub Janczura

16 September 2026 in International Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
MBMiłosz Bronowski
Miłosz Bronowski
NDNatalia Dardzińska
Natalia Dardzińska
PJPaulina Jaskulska
Paulina Jaskulska
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
JJJakub Janczura
Jakub Janczura
Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.